Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis-Reference-Cited by-同舟云学术

Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis

Published:2011-08 Issue:1-3 Volume:665 Page:29-39
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Mencarelli Andrea,Distrutti Eleonora,Renga Barbara,Cipriani Sabrina,Palladino Giuseppe,Booth Catherine,Tudor Gregory,Guse Jan-Hinrich,Hahn Ulrike,Burnet Micheal,Fiorucci Stefano

Publisher

Elsevier BV

Subject

Pharmacology

Reference38 articles.

1. New advances in antibiotic development and discovery;Alekshun;Exp. Opin. Invest. Drugs,2005

2. Erythromycin inhibits transcriptional activation of NF-B, but not NFAT, through calcineurin-independent signaling in T cells;Aoki;Antimicrob. Agents Chemother.,1999

3. Recent developments in macrolide antimicrobial research;Asaka;Curr. Med. Chem.,2003

4. Animal models of rheumatoid arthritis;Asquith;Eur. J. Immunol.,2009

5. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta;Bosnar;J. Pharmacol. Exp. Ther.,2009

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modification of Azithromycin to Mitigate its Arrest of Autophagy;2024-04-26

2. The immunomodulatory effects of probiotics and azithromycin in dextran sodium sulfate-induced ulcerative colitis in rats via TLR4-NF-κB and p38-MAPK pathway;Biomedicine & Pharmacotherapy;2023-09

3. Prospects for macrolide therapy of asthma and COPD;Advances in Pharmacology;2023

4. Modeling inflammatory bowel disease by intestinal organoids;Recent Advances in Inflammation & Allergy Drug Discovery;2022-11-21

5. The Azithromycin Pro-Drug CSY5669 Boosts Bacterial Killing While Attenuating Lung Inflammation Associated with Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus;Antimicrobial Agents and Chemotherapy;2022-09-20